Cargando…

Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review

X-linked hypophosphatemia (XLH) or vitamin D-resistant rickets (MIM#307800), is a monogenic disorder with X-linked inheritance. It is caused by mutations present in the Phosphate Regulating Endopeptidase Homolog X-Linked (PHEX) gene responsible for the degradation of the bone-derived hormone fibrobl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jurca, Claudia Maria, Iuhas, Oana, Kozma, Kinga, Petchesi, Codruta Diana, Zaha, Dana Carmen, Bembea, Marius, Jurca, Sanziana, Paul, Corina, Jurca, Alexandru Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407333/ https://www.ncbi.nlm.nih.gov/pubmed/36011303 http://dx.doi.org/10.3390/genes13081392

Ejemplares similares

Cardiofaciocutaneous syndrome – a longitudinal study of a case over 33 years: case report and review of the literature
por: Jurcă, Maria Claudia, et al.
Publicado: (2021)

Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways—Case Report and Literature Review
por: Jurca, Claudia Maria, et al.
Publicado: (2023)

Genetics of congenital solid tumors
por: Jurcă, Maria Claudia, et al.
Publicado: (2020)

Changes in skeletal dysplasia nosology
por: Jurcă, Maria Claudia, et al.
Publicado: (2021)

PAH Pathogenic Variants and Clinical Correlations in a Group of Hyperphenylalaninemia Patients from North-Western Romania
por: Iuhas, Alin, et al.
Publicado: (2023)

Greig Cephalopolysyndactyly Contiguous Gene Syndrome: Case Report and Literature Review
por: Kozma, Kinga, et al.
Publicado: (2021)

The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases
por: Țiburcă, Laura, et al.
Publicado: (2022)

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
por: Gadion, Margaux, et al.
Publicado: (2022)

Clinical Features and Outcome of Infective Endocarditis in a University Hospital in Romania
por: Babeș, Emilia Elena, et al.
Publicado: (2021)

Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone
por: Ertl, Diana-Alexandra, et al.
Publicado: (2022)

A New Frameshift Mutation of PTEN Gene Associated with Cowden Syndrome—Case Report and Brief Review of the Literature
por: Jurca, Claudia Maria, et al.
Publicado: (2023)

Correction to: Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
por: Murari, Keerti, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia
por: Lee, Sun Ku, et al.
Publicado: (2021)

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
por: Weber, Thomas J, et al.
Publicado: (2022)

Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
por: Martín Ramos, Silvia, et al.
Publicado: (2020)

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
por: Ward, Leanne M, et al.
Publicado: (2022)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
por: Schindeler, Aaron, et al.
Publicado: (2020)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
por: Brener, Avivit, et al.
Publicado: (2021)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
por: Brener, Rafi, et al.
Publicado: (2022)

Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
por: Mughal, M. Zulf, et al.
Publicado: (2023)

Dramatic Transformation After Burosumab in a Young Boy With X-linked Hypophosphatemia: A Life-Changing Saga
por: Baradhi, Krishna
Publicado: (2022)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial
por: Namba, Noriyuki, et al.
Publicado: (2022)

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level
por: Imel, Erik A, et al.
Publicado: (2023)

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
por: Insogna, Karl L, et al.
Publicado: (2019)

Treatment of Epilepsy Associated with Common Chromosomal Developmental Diseases
por: Budisteanu, Magdalena, et al.
Publicado: (2020)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review
por: Lafage-Proust, Marie-Hélène
Publicado: (2022)

Vitamin D Implications and Effect of Supplementation in Endocrine Disorders: Autoimmune Thyroid Disorders (Hashimoto’s Disease and Grave’s Disease), Diabetes Mellitus and Obesity
por: Galușca, Dorina, et al.
Publicado: (2022)

OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program
por: Carpenter, Thomas, et al.
Publicado: (2022)

Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report
por: Khadora, Manal, et al.
Publicado: (2021)

First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia
por: Cheong, Hae Il, et al.
Publicado: (2018)

Analysis of 1.2 million foot scans from North America, Europe and Asia
por: Jurca, Ales, et al.
Publicado: (2019)

Illegal Passive Smoking at Work
por: Lesage, François-Xavier, et al.
Publicado: (2011)

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
por: Padidela, Raja, et al.
Publicado: (2021)

A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome
por: Merz, Lea Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2h81hsfupefiq16os5ffkg9srh